Medullary carcinoma of thyroid is associated with which of the following gene defect?
Medullary thyroid carcinoma (MTC) is a type of thyroid cancer. I remember that it's related to the RET proto-oncogene. The RET gene is involved in several hereditary cancer syndromes, like Multiple Endocrine Neoplasia type 2 (MEN2). Specifically, germline mutations in RET cause MEN2A and MEN2B, which are associated with MTC. Somatic mutations can also occur in sporadic cases.
The options aren't provided, but the user wants the correct answer to be something like RET gene mutation. Let me confirm. Yes, RET is the key here. Other genes like BRCA1 or TP53 are related to other cancers, not MTC. So the correct answer would be RET proto-oncogene mutation.
Now, for the explanation. The core concept is that MTC is linked to RET mutations. The correct answer is RET because it's the gene responsible for the hereditary and some sporadic forms. The wrong options would be other genes like BRCA1, TP53, or maybe something else. Each of those is incorrect because they're associated with different cancers. For example, BRCA1 with breast/ovarian, TP53 with Li-Fraumeni syndrome. The clinical pearl is that RET mutations are key in MTC and that MEN2 is a major association.
**Core Concept**
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from parafollicular C-cells of the thyroid. **Germline mutations in the RET proto-oncogene** are the primary cause of hereditary MTC (associated with Multiple Endocrine Neoplasia type 2), while somatic RET mutations are seen in sporadic cases.
**Why the Correct Answer is Right**
**RET proto-oncogene mutations** activate the RET receptor tyrosine kinase, leading to constitutive signaling through pathways like MAPK/ERK and PI3K/AKT. This drives uncontrolled proliferation of C-cells. In hereditary MTC (MEN2A/MEN2B), these mutations are inherited in an autosomal dominant pattern. Somatic RET mutations in sporadic MTC similarly disrupt cell cycle regulation, promoting tumorigenesis.
**Why Each Wrong Option is Incorrect**
**Option A:** *BRCA1/2 mutations* are linked to breast, ovarian, and prostate cancers, not thyroid malignancies.
**Option B:** *TP53 mutations* are characteristic of Li-Fraumeni syndrome and various cancers (e.g., sarcomas), but not MTC.
**Option C:** *RAS mutations* are more common in differentiated thyroid cancers (papillary/follicular) than MTC.
**Option D:** *GNAS mutations* are associated with McCune-Albright syndrome and some pituitary tumors, but not MTC.
**Clinical Pearl**
Remember that **RET mutation testing is critical for MTC** to guide genetic counseling and prophylactic thyroidectomy in MEN2 families. Sporadic MTC may also harbor RET mutations, but germline testing is mandatory for hereditary cases.
**Correct